H.C. Wainwright Reaffirms Their Buy Rating on G1 Therapeutics (GTHX)

By Austin Angelo

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on G1 Therapeutics (GTHXResearch Report), with a price target of $72.00. The company’s shares closed last Monday at $22.38.

According to TipRanks.com, White is a 5-star analyst with an average return of 15.1% and a 51.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Syndax Pharmaceuticals.

G1 Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $65.20, which is a 191.6% upside from current levels. In a report released today, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Based on G1 Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $30.69 million. In comparison, last year the company had a GAAP net loss of $19.92 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.